OCX Oncocyte

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: .

An archived replay will be available after the call concludes on Oncocyte’s investor relations website at .

About Oncocyte

Oncocyte is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit for more information.

Investor Contact:

Doug Farrell

LifeSci Advisors LLC



EN
07/05/2025

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Oncocyte to Release First Quarter 2025 Results on May 12, 2025 IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 12, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: . An archived replay will be available after the c...

May 7, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Provides Positive Update on Clinical Trial Progress

Oncocyte Provides Positive Update on Clinical Trial Progress Central Institutional Review Board approved, final preparatory steps underway at first transplant centersThree of the top 10 U.S. transplant centers expected to participate in trialNearly 10% of annual U.S. transplant volume represented in trial site interestPreparing for final Q-sub FDA meeting ahead of clinical validation IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiating its...

April 30, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity

Oncocyte’s Proprietary Assay Demonstrates Long-Term Clinical Validity Transplantation Direct publication uses assay to identify rejection in patients up to 13 years post-transplant Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in BerlinSupports market expansion for testing of high-risk patient populationNew findings advance understanding of the biology of organ rejection IRVINE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced the publicatio...

April 29, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conf...

Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025. In addition, CEO Josh Riggs will participate in a fireside chat at the conference. During the event, Josh and Andrea will discuss Oncocyte’s innovative diagnostic technologies and will highlight...

April 2, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its four...

March 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch